Monday, May 31, 2021

Glenmark expects 10-12% sales growth in FY22, anticipates value unlock of its RD business

Glenmark expects 10-12% sales growth in FY22, anticipates value unlock of its RD business Sale of anti-COVID drug Fabiflu and other products fire Q1 revenues; the company spends little over $100 million annually on innovation RD business, bigger than most of its peers, developing a potential pipeline of drug assets

from Moneycontrol Business News https://ift.tt/3i62RHe
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Who is Ebrahim Raisi, Iran's president whose helicopter suffered a 'hard landing' in foggy weather?

News of his helicopter making what state media described as a "hard landing" on Sunday immediately brought new attention to the le...